Zhitong Finance App News, Harbin Pharmaceutical Co., Ltd. (600664.SH) issued an announcement. Recently, the company's subsidiary Harbin Pharmaceutical Group Pharmaceutical General Factory (“Harbin Pharmaceutical General Factory”) received the “Drug Supplement Application Approval Notice” for injectable cefazoxime sodium from the State Drug Administration [0.5g (calculated according to C13H13N5O5S2), notification number: 2026B07860; 1.0g (calculated according to C13H13N5O5S2), notification number: 2026B07866]. The quality and efficacy consistency of the above drugs through generic drugs Evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.